Xenoport, Inc. (MM) (NASDAQ:XNPT)
Historical Stock Chart
5 Years : From Mar 2010 to Mar 2015
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide
access via the World Wide Web to its presentation at the RBC Capital
Markets' Healthcare Conference. The live presentation will occur at
11:00 a.m. Pacific Time (2:00 p.m. Eastern Time) on Wednesday, February
29, 2012. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Website at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one week and
will be available approximately 24 hours after the live presentation.
XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. Horizant®
(gabapentin enacarbil) Extended-Release Tablets is XenoPort’s first U.S.
Food and Drug Administration-approved product. GlaxoSmithKline currently
holds commercialization rights and certain development rights for
gabapentin enacarbil in the United States. Regnite®
(gabapentin enacarbil) is approved for the treatment of
moderate-to-severe primary restless legs syndrome in Japan. Astellas
Pharma Inc. holds all development and commercialization rights for Regnite
in Japan and gabapentin enacarbil in five Asian countries. XenoPort
holds all other world-wide rights and has co-promotion and certain
development rights to gabapentin enacarbil in the United States.
XenoPort’s pipeline of product candidates includes potential treatments
for patients with postherpetic neuralgia, spasticity and Parkinson’s
To learn more about XenoPort, please visit the Website at www.XenoPort.com.
XENOPORT is a registered trademark of XenoPort, Inc.
Horizant is a registered trademark of GlaxoSmithKline.
Regnite is a registered trademark of Astellas Pharma Inc.